AcquisitionOther
KINETA, INC./DE acquired Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
KINETA, INC./DE -> Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor · $9,005,000
Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA’s late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURA’s therapeutic focus on over
Open source record (SEC) ↗